Facebook
X
LinkedIn
Forward12th Annual Updates from ASH: Practice-Changing Abstracts
Chicago, IL US
January 29, 2027
From the Latest Science to Better Patient Care
Join community-based healthcare professionals and academic hematology/oncology experts for an engaging day filled with the most important scientific advances presented at the 2026 American Society of Hematology Annual Meeting.
Through expert presentations and interactive discussion, explore emerging data on transplant and cellular therapies, novel immunotherapies, targeted agents, and other evolving strategies for treating hematologic malignancies. Faculty will put the latest research into context, offering practical insights to help you navigate treatment selection and sequencing, incorporate new evidence into patient management, and identify opportunities for specialized care and clinical trials.
Turn the latest discoveries into meaningful changes in practice. Join us in Chicago. Register today!
Learn more at the conference website!
Target Audience
This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and all healthcare professionals dedicated to the treatment of hematologic cancers.
Learning Objectives
After this activity, participants will be able to:
- Describe the clinical implications of key practice-changing data presented at the 2026 American Society of Hematology Annual Meeting.
- Explain the pathogenesis, diagnostic evaluation, and current therapeutic approaches for common classical hematologic disorders, including newly approved therapeutic classes such as menin inhibitors and next-generation BCL-2 inhibitors.
- Apply current evidence to optimize patient selection, timing, and conditioning strategies for stem cell transplantation in patients with high-risk and relapsed/refractory hematologic malignancies.
- Interpret emerging clinical trial evidence evaluating cellular therapies for hematologic malignancies to inform evolving standards of care.
- Differentiate the roles of targeted therapies, cellular therapies, and clinical trial options across treatment pathways for patients with lymphoid malignancies, including relapsed/refractory disease.
- Compare evolving treatment paradigms and sequencing strategies for patients with multiple myeloma, including CAR T-cell therapies, BCMA- and GPRC5D-directed bispecific antibodies, and dual-antigen targeting approaches.
- Evaluate treatment sequencing strategies for patients with lymphoma by integrating evidence for novel agents across newly diagnosed and relapsed/refractory disease settings.
- Assess international trends in the management of hematologic malignancies for their relevance to local clinical practice.
View the Complete Program
Explore the full agenda, including session topics, times, and faculty.
Swissotel Chicago
323 East Wacker Drive
Chicago, IL
60601
United States
HYBRID CONFERENCE
Designed by renowned Chicago architect Harry Weese, Swissôtel Chicago is an award-winning luxury hotel overlooking the Chicago River and Lake Michigan, and just steps from the Magnificent Mile. The distinctive 4-diamond, all-glass hotel offers spectacular wrap-around views from Navy Pier to Millennium Park, 662 guest rooms and suites, five premier ballrooms, a state-of-the-art penthouse fitness center, and spotless European-style service.
VISITING CHICAGO
Discover why Condé Nast Traveler readers voted Chicago the Best Big City in the U.S. for a historic ninth year in a row. To help plan your stay in Chicago, visit Choose Chicago.
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact Meeting Achievements via email.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, the University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
UNIVERSITY OF CHICAGO COURSE DIRECTOR
Michael R. Bishop, MD
Professor of Medicine
Director, Jonas Center for Cellular Therapy
Director, Hematopoietic Stem Cell Transplantation Program
Professor of Medicine
Director, Jonas Center for Cellular Therapy
Director, Hematopoietic Stem Cell Transplantation Program
Disclosure Declarations
As a provider accredited by the ACCME, the University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an educational activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships before the start of the activity.
Additionally, the University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, the University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an educational activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships before the start of the activity.
Additionally, the University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 6.75 contact hours.
Pharmacy Credit
Pinnacle Conference, LLC is providing ACPE continuing pharmacy education credit for this activity. To receive CPE credit through CPE Monitor, please ensure you have provided your NABP ePID number and DOB appropriately. If you are unsure or would like to confirm, please contact [email protected] within 60 days of completing the activity.
American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other Participant Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please note: The credit-claiming process closes 1 month after the activity ends. Requests submitted more than 1 month after the event date may incur additional fees.
EXHIBIT AND SPONSORSHIP OPPORTUNITIES ARE AVAILABLE!
Connect with the professionals shaping the future of hematologic cancer care!
As new therapies and treatment strategies continue to transform hematologic oncology, this conference brings together clinicians and other healthcare professionals eager to explore the latest advances and their implications for patient care. Exhibiting or sponsoring offers your organization a valuable opportunity to connect with this engaged audience, showcase your innovations, and build meaningful relationships.
With an anticipated 250 in-person attendees, this is a valuable opportunity to showcase your organization, build meaningful connections, and increase your visibility among professionals dedicated to advancing cancer care.
Why Participate?
- Connect with your audience: Engage directly with clinicians, researchers, and healthcare professionals from academic and community practice settings.
- Showcase your innovations: Highlight your therapies, technologies, and patient support solutions to professionals interested in the latest advances in hematologic oncology.
- Expand your visibility: Choose from exhibit packages, event sponsorships, branded experiences, and digital advertising opportunities.
- Make meaningful connections: Take advantage of dedicated exhibit breaks, networking opportunities, and face-to-face conversations with conference attendees.
Space is limited, so reserve your opportunity today!
Explore the available packages and participation details in the 
Exhibitor & Sponsorship Prospectus, or contact Kristen Shepard by email for more information.
We look forward to welcoming you to Chicago!
Registration: Visit the registration website by clicking below!
Early rates expire on December 19, and space is limited, so reserve your spot today.
Early rates expire on December 19, and space is limited, so reserve your spot today.
Profession Type | In Person | Virtual |
|---|---|---|
Physicians | $100/$125 | $50/$60 |
Nurses, Pharmacists, Other Healthcare Professionals | $45/$60 | $30/$40 |
Residents & Fellows | $25 | $25 |
UChicago Faculty & Staff | $25 | $0 |
Industry | $495 | $195 |
UChicago staff: Registration fees will be refunded upon confirmed attendance. Please register using the UChicago Employee registration type. Fellows/Trainees/Residents: Registration fees will be refunded upon confirmed attendance. Please register using the Trainee fees. Refunds will be processed within 3-5 business days of the conclusion of the event. | ||
Cancellation Policy: Please see the registration site for the full details. | ||
Claiming Credit: After creating an account or logging in, enter the access code to unlock the credit-claiming process.
Please note: The credit-claiming process closes 1 month after the activity ends. Requests submitted more than 1 month after the event date may incur additional fees.
Please login or create an account to proceed.